AptarGroup Reports Q3 2026 Sales Growth Amidst Margin Compression and Russian Deconsolidation
AptarGroup (ATR) reported third-quarter sales of $1.02 billion, a 6% increase driven by broad demand across its Beauty, Closures, and Pharma segments. Despite the revenue growth, adjusted earnings per share fell 6% to $1.52 due to higher interest expenses, an increased effective tax rate, and margin dilution caused by a shift in product mix. The company faced significant headwinds including a $61.2 million pre-tax loss from the deconsolidation of its Russian subsidiary and lower high-margin emergency medicine sales. While segments like Closures (11% growth) and Injectables (9% growth) showed strength, management noted operational challenges in North American Beauty operations and uncertainty regarding future naloxone demand trajectories.